Nuvation Bio Inc.

NYSE:NUVB

Biotechnology

Healthcare
$3.81 +1.03%

+$0.06 today

Market cap
$1.34B
Beta
1.56
P/E (TTM)
-12.8
EPS (TTM)
-$0.42
52W Low $1.81High $9.75

Volume 9.92M

Average 4.07M

Fair Value & DCF

Compare our fair value with your own assumptions

Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.

Nuvation Bio Inc.

NYSE:NUVB

Intrinsic Alpha fair value

Locked

Current Price

$3.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Build your own valuation

Test an independent scenario and compare it with Intrinsic Alpha's estimate.

Sign in to use the DCF calculator

Free accounts get 5 valuations per week. Upgrade for more.

Sign in / Sign up

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
+64.1% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Forward estimates point to Revenue at +64.1% (5yr), giving you a quick read on expected growth from here.

Estimates & History

Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.

Further estimates hidden. Sign in to unlock

Competitor Valuations

Peer stocks ranked by intrinsic value status

CompanyMarket CapPriceValuationP/E1Y Return

Edgewise Therapeutics, Inc.

NASDAQ:EWTX

$4.94B$45.93Not rated-21.9+84.29%

AbCellera Biologics Inc.

NASDAQ:ABCL

$3.75B$11.49Not rated-11.4+190.03%

Viridian Therapeutics, Inc.

NASDAQ:VRDN

$3.51B$30.87Not rated-4.7+9.62%

Celldex Therapeutics, Inc.

NASDAQ:CLDX

$2.26B$28.83Not rated-7.8+12.20%

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

$2.11B$15.73Undervalued7.2-2.04%

Vera Therapeutics, Inc.

NASDAQ:VERA

$2.03B$28.10Not rated-6.8-6.30%

uniQure N.V.

NASDAQ:QURE

$1.67B$23.81Not rated-14.1-27.62%

Ocular Therapeutix, Inc.

NASDAQ:OCUL

$1.37B$6.21Not rated-7.3-51.57%

Structure Therapeutics Inc.

NASDAQ:GPCR

$1.15B$20.00Not rated-19.3-53.11%

Janux Therapeutics, Inc.

NASDAQ:JANX

$695.66M$11.37Not rated-7.6-64.28%